Table 4 Pretransplant characteristics in adult DDLT and LDLT patients.

From: Pre-transplant predictors of 3-Month survival following liver transplantation for acute liver failure in adult and pediatric patients in Türkiye

 

Before propensity matching

After propensity matching*

 

Total

DDLT

LDLT

p

Total

DDLT

LDLT

p

n

236

101

135

 

92

46

46

 

Age

33.7

(32.0-36.8)

37.4

(33.5–41.6)

32.1

(29.5–35.1)

0.037

32.7

(29.5–36.4)

32.9

(29-37.5)

32.7

(28.1–36.9)

0.969

Gender Female, n (%)

143 (60.6)

60 (59.4)

83 (61.5)

0.788

58 (63.0)

26 (56.5)

32 (69.5)

0.280

BMI

24.5

(24.1–25.1)

24.6

(23.9–25.4)

24.2

(23.5–25.3)

0.617

24.5

(23.9–25.4)

24.5

(23.1–25.8)

24.7

(23.6–25.7)

0.942

Bilirubin (mg/dL)

15.6

(14.0-17.3)

16.5

(14.6–19.2)

14.6

(12.5–19.1)

0.563

16.6

(12.2–22.0)

16.8

(11.0-22.8)

16.0

(11.4–24.6)

0.702

Albumin (mg/dL)

2.9

(2.8-3.0)

2.9

(2.8–3.1)

2.8

(2.7-3.0)

0.856

2.9

(2.7-3)

3

(2.79–3.2)

2.7

(2.59–2.91)

0.177

INR

3.3

(3.0-3.6)

3.2

(2.8–3.6)

3.4

(3.0-3.8)

0.100

3.38

(2.8-4)

3.5

(2.8–4.11)

3.25

(2.84–4.3)

0.563

Creatinine (mg/dL)

0.70

(0.64–0.70)

0.70

(0.69–0.83)

0.66

(0.60–0.70)

0.045

0.66

(0.6–0.7)

0.7

(0.64–0.86)

0.6

(0.59–0.7)

0.084

Sodium (mEq/L)

137

(137–138)

137.5

(136–139)

137

(136–139)

0.749

137.5

(136.1–139)

137

(134–139)

138

(136-139.1)

0.547

Lactate (mmol/L)

3.22

(3.11–3.55)

3.15

(2.89–3.92)

3.30

(3.11–3.65)

0.832

3.11

(2.9–3.6)

2.99

(2.66–3.59)

3.11

(2.84–3.66)

0.947

Ammonia (µmol/L)

231

(217–245)

216

(175–240)

240

(220–260)

0.014

220

(185–240)

220

(160–246)

229.2

(185–241)

0.514

pH

7.4

(7.4–7.4)

7.4

(7.4–7.4)

7.4

(7.4–7.4)

0.418

7.4

(7.4–7.4)

7.4

(7.4–7.4)

7.4

(7.4–7.4)

0.846

Waiting time (day)

4

(4–5)

4

(4–5)

4

(4–5)

0.552

4

(3–4)

4

(3–4)

4

(3–5)

0.767

HE Stages, n (%)

 

1

8 (3.4)

4 (4.0)

4 (3.0)

0.020

4 (4.3)

2 (4.3)

2 (4.3)

1.000

2

43 (18.2)

15 (14.9)

28 (20.7)

16 (17.4)

8 (17.4)

8 (17.4)

3

86 (36.4)

28 (27.7)

58 (43.0)

36 (39.1)

18 (39.1)

18 (39.1)

4

89 (37.7)

47 (46.5)

42 (31.1)

36 (39.1)

18 (39.1)

18 (39.1)

Not defined

10 (4.2)

7 (6.9)

3 (2.2)

0

0

0

Etiologies, n (%)

 

Viral

76 (32.2)

26 (25.7)

50 (37.0)

0.0054

31 (33.7)

13 (28.3)

18 (39.1)

0.272

DILI

44 (18.6)

21 (20.8)

23 (17.0)

14 (15.2)

9 (19.6)

5 (10.9)

Indeterminate

64 (27.1)

22 (21.8)

42 (31.1)

27 (29.3)

10 (21.7)

17 (37.0)

Budd-Chiari syndrome

7 (3.0)

4 (4.0)

3 (2.2)

3 (3.3)

2 (4.3)

1 (2.2)

Pregnancy-related

4 (1.7)

1 (1.0)

3 (2.2)

3 (3.3)

1 (2.2)

2 (4.3)

Hemochromatosis

1 (0.4)

1 (1.0)

0 (0)

1 (1.1)

1 (2.2)

0 (0)

Autoimmune hepatitis

7 (3.0)

4 (4.0)

3 (2.2)

2 (2.2)

2 (4.3)

0 (0)

Wilson’s disease

11 (4.7)

10 (9.9)

1 (0.7)

5 (5.4)

4 (8.7)

1 (2.2)

Mushroom

18 (7.6)

8 (7.9)

10 (7.4)

6 (6.5)

4 (8.7)

2 (4.3)

Acute ischemic injury

4 (1.7)

4 (4.0)

0 (0)

0 (0)

0 (0)

0 (0)

  1. *: Pre-transplant values obtained after matching living donor and cadaveric donor transplant patients for age, creatinine, ammonia and hepatic encephalopathy stages.
  2. BMI, body mass index; INR, international normalized ratio; HE, hepatic encephalopathy; LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; DILI, drug-induced liver injury.
  3. Data are presented as median (95% confidence interval) unless otherwise indicated.
Back to article page